Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01692899

Acronym

MAINTAIN

Enrollment

780

Registered

2012-09-25

Start date

2011-06-30

Completion date

2011-09-30

Last updated

2012-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Retention Rates, of Adalimumab, Etanercept and Infliximab, as First and Second-Line Biotherapy, in Patients with Rheumatoid Arthritis, in Daily Practice., TNF inhibitors, biotherapy, retrospective study

Brief summary

To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line tumor necrosis factor α inhibitors (TNFi).

Detailed description

In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done after adjustment using a Cox model. Factors associated with better retention were identified by multivariate analysis. Medical charts of all patients with RA starting a first TNFα inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France) and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in detail by 2 rheumatologist investigators

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* RA defined by the 1987 ACR criteria \[18\] * first TNFα inhibitor prescribed in the previously mentioned period * TNFα inhibitor prescribed as first-line biotherapy * undergone at least one evaluation in the center after treatment initiation

Exclusion criteria

* previously received another biotherapy * TNFα inhibitor was prescribed in an RCT * refused to participate

Design outcomes

Primary

Measure	Time frame
Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA	2 years

Secondary

Measure	Time frame
Compare retention rates of TNFα inhibitor monoclonal antibodies (adalimumab and infliximab) and the soluble receptor (etanercept)	4 years
Causes of discontinuing these treatments	4 years
Determine the factors associated with better retention of the first TNFα inhibitors	4 years
Compare retention rates of possible second-line TNFα inhibitors	4 years

Outcome results